IDL Diagnostics Q2 FY26 operating loss narrows to SEK 1.09 million; revenue rises 43.5% to SEK 14.56 million vs Q2 FY25

• IDL Diagnostics posted Q2 operating loss of SEK 1.09 million, narrowing from a deeper loss a year earlier.
• Revenue rose 43.5% to SEK 14.56 million; gross margin strengthened 12.6 percentage points to 59.9%.
• Net loss attributable to shareholders narrowed to SEK 1.08 million; cash and cash equivalents totaled SEK 35.31 million at June 30.
• Gustav Sten took over as CEO on May 28, succeeding Anders Hultman after eight years with the company.
• Management cited strong order intake; urology sales increased 50% year-on-year, while infectious diseases grew 32%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDL Diagnostics AB (publ) published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.